Skip to main content
GANX
NASDAQ Life Sciences

Gain Therapeutics' Parkinson's Drug Shows 81% Biomarker Reduction; New Candidate Advances to IND-Enabling Studies

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.9
Mkt Cap
$75.386M
52W Low
$1.41
52W High
$4.34
52W Position info
35% above low
Off High info
56% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

GANX sits 35% above its 52-week low of $1.41.

Summary

Gain Therapeutics reported its Q4 and FY25 financial results and provided a significant corporate update. The company detailed positive clinical and biomarker data from its Phase 1b study of GT-02287 for Parkinson's disease, notably an 81% average reduction in glucosylsphingosine (GluSph) in cerebrospinal fluid and stable MDS-UPDRS scores over 150 days. This elaborates on the positive data announced in the March 18th 8-K, providing critical quantitative evidence of GT-02287's disease-modifying potential. Furthermore, Gain Therapeutics announced that a new lead candidate, GT-04686, is ready for IND-enabling studies for Parkinson's and other neurological disorders, significantly expanding its pipeline. The company is also engaging with the FDA for GT-02287 Phase 2 clinical development. This comprehensive update, featuring strong biomarker data and pipeline expansion, is highly material for a clinical-stage biotech. Investors should monitor the completion of the GT-02287 extension study in September 2026 and the progress of GT-04686 into IND-enabling studies.

At the time of this announcement, GANX was trading at $1.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $75.4M. The 52-week trading range was $1.41 to $4.34. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

GANX - Latest Insights

GANX
Nov 10, 2026, 4:07 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.08
Real-time Price: $1.00 info
Change: -$0.080 (-7%) info
Market Cap: $44.499M info
GANX
Oct 01, 2026, 9:28 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.74
Real-time Price: $1.00 info
Change: -$0.740 (-43%) info
Market Cap: $44.499M info
GANX
Oct 01, 2026, 9:16 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.75
Real-time Price: $1.00 info
Change: -$0.7525 (-43%) info
Market Cap: $44.499M info
GANX
Aug 11, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.00
Real-time Price: $1.00 info
Change: -$1.00 (-50%) info
Market Cap: $44.499M info
GANX
Aug 11, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.06
Real-time Price: $1.00 info
Change: -$1.06 (-51%) info
Market Cap: $44.499M info